Gadobutrol

FDA Approved: * November 17, 2022
Pharm Company: * HENGRUI PHARMA
Category: Diagnostic Aid

Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and the United States.[1][2][3][4] As of 2007, it was the only GBCA approved at 1.0 molar concentrations.[5] Gadobutrol is marketed by Bayer AG as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist.[6] In India, it is also marketed by Vivere Imaging as Viv-butrol.&a... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Gadobutrol 604.72 mg/ml Intravenous Injection
NDC: 65219-281
Labeler:
Fresenius Kabi USA, LLC
Gadobutrol 604.72 mg/ml Intravenous Injection
NDC: 65219-287
Labeler:
Fresenius Kabi USA, LLC
Gadobutrol 604.72 mg/ml Intravenous Injection
NDC: 65219-289
Labeler:
Fresenius Kabi USA, LLC
Gadobutrol 604.72 mg/ml Intravenous Injection
NDC: 70436-122
Labeler:
Slate Run Pharmaceuticals, LLC
Gadobutrol 604.72 mg/ml Intravenous Injection
NDC: 70436-212
Labeler:
Slate Run Pharmaceuticals, LLC
Gadobutrol 604.72 mg/ml Intravenous Injection
NDC: 70436-214
Labeler:
Slate Run Pharmaceuticals, LLC

Related Brands

Drugs with the same active ingredients